share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

福泰制药 | 4:持股变动声明-高管 Kewalramani Reshma
美股SEC公告 ·  05/22 16:26
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of common stock on May 20, 2024. The transaction was executed at a price of $447.00 per share, resulting in a total sale value of $6,795,294. Following the sale, Reshma's direct holdings in the company amount to 121,374 shares. The sale took place in an open market transaction, as reported by Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of common stock on May 20, 2024. The transaction was executed at a price of $447.00 per share, resulting in a total sale value of $6,795,294. Following the sale, Reshma's direct holdings in the company amount to 121,374 shares. The sale took place in an open market transaction, as reported by Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals首席执行官兼总裁Kewalramani Reshma于2024年5月20日完成了15,202股普通股的出售。该交易以每股447.00美元的价格执行,总销售价值为6,795,294美元。出售后,雷什玛在该公司的直接持股量为121,374股。据Vertex Pharmicals Inc.报道,此次出售是在公开市场交易中进行的。
Vertex Pharmaceuticals首席执行官兼总裁Kewalramani Reshma于2024年5月20日完成了15,202股普通股的出售。该交易以每股447.00美元的价格执行,总销售价值为6,795,294美元。出售后,雷什玛在该公司的直接持股量为121,374股。据Vertex Pharmicals Inc.报道,此次出售是在公开市场交易中进行的。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息